title: Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
abstract: In December 2005, 11 Canadian hematologists met to develop an evidence-based clinical practice guideline that would address the diagnosis, monitoring, management, and rationale for the treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). This Expert Panel consisted of hematologists from across Canada, each with an active practice in a major population centre or a rural area. Based on an extensive literature search and years of clinical experience, their mandate was to address common clinical practice questions, particularly why treat, whom to treat, when to initiate treatment, and how to treat iron overload in patients with MDS.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Wells
authors.forename: Brian
authors.initials: B
authors.lastname: Leber
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Lipton
authors.forename: Wanda
authors.initials: W
authors.lastname: Hasegawa
authors.forename: Kuljit
authors.initials: K
authors.lastname: Grewal
authors.forename: Karen
authors.initials: K
authors.lastname: Yee
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Olney
authors.forename: Loree
authors.initials: L
authors.lastname: Larratt
authors.forename: Linda
authors.initials: L
authors.lastname: Vickars
authors.forename: Alan
authors.initials: A
authors.lastname: Tinmouth
mesh_terms: D006801:Humans; D002170:Canada; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy; D011379:Prognosis; D065227:Transfusion Reaction
chemical_list: D007502:Iron Chelating Agents